ID   CHLA-60
AC   CVCL_6607
DR   Cosmic; 930043
DR   Wikidata; Q54812504
RX   PubMed=11212268;
RX   PubMed=24792489;
CC   Doubling time: 96 hours (COG).
ST   Source(s): COG
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 11,13
ST   D18S51: 15
ST   D19S433: 15
ST   D21S11: 28,30
ST   D2S1338: 23
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 7,10
ST   D8S1179: 13,14
ST   FGA: 23,26
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_AQ17 ! CHLA-61
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 10
//
RX   PubMed=11212268;
RA   Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P.,
RA   Brodeur G.M., White P.S.;
RT   "Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36
RT   or at other tumor suppressor loci in neuroblastoma.";
RL   Cancer Res. 61:679-686(2001).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//